Binding Inhibitors of the Beta-Transducin Repeat-Containing Protein

Mark Bradley; Jeffrey Walton; Sunay Chankeshwara; Mazen Haj Sleiman; G. S. Baillie; Lucien Gibson

Binding Inhibitors of the Beta-Transducin Repeat-Containing Protein

Mark Bradley (Inventor), Jeffrey Walton (Inventor), Sunay Chankeshwara (Inventor), Mazen Haj Sleiman (Inventor), G. S. Baillie (Inventor), Lucien Gibson (Inventor)

Research output: Patent

Abstract

The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of l3TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.

Original language	English
Patent number	WO 2013/001297
IPC	C07K 7/06 (2006.01), C07K 14/47 (2006.01)
Priority date	27/06/11
Publication status	Published - 3 Jan 2013

Cite this

@misc{e5e39a2765cd4ba8a6fdee2001b64894,

title = "Binding Inhibitors of the Beta-Transducin Repeat-Containing Protein",

abstract = "The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of l3TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.",

author = "Mark Bradley and Jeffrey Walton and Sunay Chankeshwara and \{Haj Sleiman\}, Mazen and Baillie, \{G. S.\} and Lucien Gibson",

year = "2013",

month = jan,

day = "3",

language = "English",

type = "Patent",

note = "WO 2013/001297; C07K 7/06 (2006.01), C07K 14/47 (2006.01)",

}

TY - PAT

T1 - Binding Inhibitors of the Beta-Transducin Repeat-Containing Protein

AU - Bradley, Mark

AU - Walton, Jeffrey

AU - Chankeshwara, Sunay

AU - Haj Sleiman, Mazen

AU - Baillie, G. S.

AU - Gibson, Lucien

PY - 2013/1/3

Y1 - 2013/1/3

N2 - The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of l3TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.

AB - The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of l3TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.

M3 - Patent

M1 - WO 2013/001297

ER -

Binding Inhibitors of the Beta-Transducin Repeat-Containing Protein

Abstract

Fingerprint

Cite this